Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK‐432 for resectable pancreatic cancer patients

Hisahito Endo, Takuro Saito, Akira Kenjo, Mika Hoshino, Masanori Terashima, Tetsu Sato, Takayuki Anazawa, Takashi Kimura, Atsushi Irisawa, Hiromasa Ohira,

Journal of Hepato-Biliary-Pancreatic Sciences · 2011 · 50 citations · 28 references

Concepts

Abstract

PURPOSE: To determine the feasibility, safety and histological change of preoperative endoscopic ultrasound-guided fine-needle injection (PEU-FNI) of immature DCs (iDCs) with OK-432 in pancreatic cancer patients. METHODS: Nine patients enrolled in the trial (DC group) and were compared with 15 patients operated on without iDC injection (non-DC group). Adverse events of PEU-FNI and postoperative complications were evaluated according to CTC-AE ver.3.0 and the Clavien-Dindo classification/ISGPF definition, respectively. Histological changes within the tumor and lymph nodes were evaluated by immunohistochemical examination of infiltrating inflammatory cells (CD4+, CD8+, Foxp3+ and CD83+). RESULTS: There were no severe toxicities following PEU-FNI, except for one transient grade 3 fever, and there were no significant differences in the incidence of postoperative complications between the two groups. Colliquative necrosis and diffusely scattered TUNEL-positive cells were observed at the injection sites. CD83+ cells significantly accumulated in the regional lymph nodes of the DC group as well as Foxp3+ cells in the regional and distant lymph nodes. The two DC group patients, one of which was stage IV with distant lymph node metastasis, survived more than 5 years without requiring adjuvant theraphy. CONCLUSION: PEU-FNI was feasible and safe, and further study needs to confirm and enhance antitumor responses.

References

28